Regenerative medicine interventions for orthopedic disorders: Ethical issues in the translation into patients

Regenerative Medicine

Volumn 8, Issue 1, 2013, Pages 65-73

  Niemansburg, Sophie L ^a   Van Delden, Johannes J M ^a   Dhert, Wouter J A ^a   Bredenoord, Annelien L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

clinical trials; comparator; first in human trial; intervertebral disc disease; musculoskeletal; osteoarthritis; outcome measures; participant selection; research ethics; risk:benefit ratio

Indexed keywords

ALLOTRANSPLANTATION; ARTHROSCOPIC SURGERY; AUTOTRANSPLANTATION; CELL THERAPY; CLINICAL RESEARCH; CONTROLLED STUDY; GENE TRANSFER; HUMAN; INTERVERTEBRAL DISK DISEASE; KNEE OSTEOARTHRITIS; MEDICAL ETHICS; MUSCULOSKELETAL DISEASE; ORTHOPEDICS; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; RISK BENEFIT ANALYSIS; TISSUE ENGINEERING;

ANIMALS; BONE DISEASES; HUMANS; ORTHOPEDICS; OUTCOME ASSESSMENT (HEALTH CARE); REGENERATIVE MEDICINE; RISK FACTORS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84871583959     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.12.112     Document Type: Review

References (50)

1. Atala A. Engineering tissues, organs and cells. J. Tissue Eng. Regen. Med. 1(2), 83-96 (2007).
2. Daar AS, Greenwood HL. A proposed definition of regenerative medicine. J. Tissue Eng. Regen. Med. 1(3), 179-184 (2007).
3. Noth U, Rackwitz L, Steinert AF, Tuan RS. Cell delivery therapeutics for musculoskeletal regeneration. Adv. Drug Deliv. Rev. 62(7-8), 765-783 (2010).
4. Atala A, Lanza R, Thomson J, Nerem R. Cell-based therapies for musculoskeletal repair. In: Foundations of Regenerative Medicine. Elsevier, CA, USA, 478-501 (2010).
5. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull. World Health Organ. 81(9), 646-656 (2003).
6. Trommelmans L, Selling J, Dierickx K. An exploratory survey on the views of European tissue engineers concerning the ethical issues of tissue engineering research. Tissue Eng. Part B Rev. 15(3), 241-247 (2009).
7. Emanuel EJ, Grady C, Crouch RA, Lie R, Miller FG, Wendler D. An ethical framework for biomedical research. In: The Oxford Textbook of Clinical Research Ethics. Oxford University Press, NY, USA, 123-135 (2010).
8. Bernabe RD, van Thiel GJ, Raaijmakers JA, van Delden JJ. The risk-benefit task of research ethics committees: an evaluation of current approaches and the need to incorporate decision studies methods. BMC Med. Ethics 13(1), 6 (2012).
9. Bernabe RD, van Thiel GJ, Raaijmakers JA, van Delden JJ. The need to explicate the ethical evaluation tools to avoid ethical inflation. Am. J. Bioeth. 9(11), 56-58 (2009).
10. Weijer C. The ethical analysis of risk. J. Law Med. Ethics 28(4), 344-361 (2000).
11. Trommelmans L, Selling J, Dierickx K. Ethical reflections on clinical trials with human tissue engineered products. J. Med. Ethics 34(9), e1 (2008).
12. Schneider CK, Salmikangas P, Jilma B et al. Challenges with advanced therapy medicinal products and how to meet them. Nat. Rev. Drug Discov. 9(3), 195-201 (2010).
13. Roberts S, Genever P, McCaskie A, De Bari C. Prospects of stem cell therapy in osteoarthritis. Regen. Med. 6(3), 351-366 (2011).
14. Carragee EJ, Don AS, Hurwitz EL, Cuellar JM, Carrino JA, Herzog R. 2009 ISSLS prize winner: does discography cause accelerated progression of degeneration changes in the lumbar disc: a ten-year matched cohort study. Spine (Phila Pa 1976) 34(21), 2338-2345 (2009).
15. Kimmelman J. Valuing risk: the ethical review of clinical trial safety. Kennedy Inst. Ethics J. 14(4), 369-393 (2004).
16. Trommelmans L, Selling J, Dierickx K. Informing participants in clinical trials with ex vivo human tissue-engineered products: what to tell and how to tell it? J. Tissue Eng. Regen. Med. 2(4), 236-241 (2008).
17. King NM. Defining and describing benefit appropriately in clinical trials. J. Law Med. Ethics 28(4), 332-343 (2000).
18. Appelbaum PS, Roth LH, Lidz CW, Benson P, Winslade W. False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent. Rep. 17(2), 20-24 (1987).
19. Kimmelman J. Gene Transfer and the Ethics of First-in-Human Research, Lost in Translation. Cambridge University Press, UK (2010).
20. Anderson JA, Kimmelman J. Are Phase I trials therapeutic? Risk, ethics, and division of labor. Bioethics doi:10. 1111/j. 1467-8519. 2012. 01979. x (2012) (Epub ahead of print).
21. Carr AJ, Robertsson O, Graves S et al. Knee replacement. Lancet 379(9823), 1331-1340 (2012).
22. Kwon B, Katz JN, Kim DH, Jenis LG. A review of the 2001 Volvo Award winner in clinical studies: lumbar fusion versus nonsurgical treatment for chronic low back pain: a multicenter randomized controlled trial from the Swedish lumbar spine study group. Spine (Phila Pa 1976) 31(2), 245-249 (2006).
23. Errico TJ, Gatchel RJ, Schofferman J et al. A fair and balanced view of spine fusion surgery. Spine J. 4(5 Suppl. ), S129-S138 (2004).
24. Cheung KM, Karppinen J, Chan D et al. Prevalence and pattern of lumbar magnetic resonance imaging changes in a population study of one thousand forty-three individuals. Spine (Phila Pa 1976) 34(9), 934-940 (2009).
25. Endean A, Palmer KT, Coggon D. Potential of magnetic resonance imaging findings to refine case definition for mechanical low back pain in epidemiological studies: a systematic review. Spine (Phila Pa 1976) 36(2), 160-169 (2011).
26. Link TM, Steinbach LS, Ghosh S et al. Osteoarthritis: MR imaging findings in different stages of disease and correlation with clinical findings. Radiology 226(2), 373-381 (2003).
27. Jarvik JJ, Hollingworth W, Heagerty P, Haynor DR, Deyo RA. The Longitudinal Assessment of Imaging and Disability of the Back (LAIDBack) study: baseline data. Spine (Phila Pa 1976) 26(10), 1158-1166 (2001).
28. Deyo RA. Diagnostic evaluation of LBP: reaching a specific diagnosis is often impossible. Arch. Intern. Med. 162(13), 1444-1447 (2002).
29. Trommelmans L, Selling J, Dierickx K. Is tissue engineering a new paradigm in medicine? Consequences for the ethical evaluation of tissue engineering research. Med. Health Care Philos. 12(4), 459-467 (2009).
30. van der Graaf R, van Delden JJ. What is the best standard for the standard of care in clinical research? Am. J. Bioeth. 9(3), 35-43 (2009).
31. Harris JD, Siston RA, Pan X, Flanigan DC. Autologous chondrocyte implantation: a systematic review. J. Bone Joint Surg. Am. 92(12), 2220-2233 (2010).
32. Trommelmans L, Dierickx K. Standard of care in clinical research with human tissue engineered products (HTEPs). Am. J. Bioeth. 9(3), 44-45 (2009).
33. Horng S, Miller FG. Ethical framework for the use of sham procedures in clinical trials. Crit. Care Med. 31(3 Suppl. ), S126-S130 (2003).
34. Miller FG. Sham surgery: an ethical analysis. Sci. Eng. Ethics 10(1), 157-166 (2004).
35. Campbell MK, Entwistle VA, Cuthbertson BH et al. Developing a placebo-controlled trial in surgery: issues of design, acceptability and feasibility. Trials 12, 50 (2011).
36. Macklin R. The ethical problems with sham surgery in clinical research. N. Engl. J. Med. 341(13), 992-996 (1999).
37. Evans CH, Ghivizzani SC, Robbins PD. Progress and prospects: genetic treatments for disorders of bones and joints. Gene Ther. 16(8), 944-952 (2009).
38. Dresser R. First-in-human trial participants: not a vulnerable population, but vulnerable nonetheless. J. Law Med. Ethics 37(1), 38-50 (2009).
39. Bretzner F, Gilbert F, Baylis F, Brownstone RM. Target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell 8(5), 468-475 (2011).
40. Chan BP, Leong KW. Scaffolding in tissue engineering: general approaches and tissue-specific considerations. Eur. Spine J. 17(Suppl. 4), 467-479 (2008).
41. Kandel R, Roberts S, Urban JP. Tissue engineering and the intervertebral disc: the challenges. Eur. Spine J. 17(Suppl. 4), 480-491 (2008).
42. Lund T, Oxland TR. Adjacent level disk disease-is it really a fusion disease? Orthop. Clin. North Am. 42(4), 529-541, viii (2011).
43. Masuda K. Biological repair of the degenerated intervertebral disc by the injection of growth factors. Eur. Spine J. 17(Suppl. 4), 441-451 (2008).
44. Axelrad TW, Einhorn TA. Bone morphogenetic proteins in orthopaedic surgery. Cytokine Growth Factor Rev. 20(5-6), 481-488 (2009).
45. Clouet J, Vinatier C, Merceron C et al. From osteoarthritis treatments to future regenerative therapies for cartilage. Drug Discov. Today 14(19-20), 913-925 (2009).
46. Evans CH, Ghivizzani SC, Robbins PD. Orthopedic gene therapy in 2008. Mol. Ther. 17(2), 231-244 (2009).
47. Paesold G, Nerlich AG, Boos N. Biological treatment strategies for disc degeneration: potentials and shortcomings. Eur. Spine J. 16(4), 447-468 (2007).
48. Anderson DG, Risbud MV, Shapiro IM, Vaccaro AR, Albert TJ. Cell-based therapy for disc repair. Spine J. 5(6 Suppl. ), 297S-303S (2005).
49. Kock L, van Donkelaar CC, Ito K. Tissue engineering of functional articular cartilage: the current status. Cell Tissue Res. 347(3), 613-627 (2012).
50. McCullen SD, Chow AG, Stevens MM. In vivo tissue engineering of musculoskeletal tissues. Curr. Opin. Biotechnol. 22(5), 715-720 (2011).